Compare KraneShares CSI China Internet ETF (KWEB) vs Tilray Brands Inc (TLRY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KraneShares CSI China Internet ETF vs Tilray Brands Inc — how do they compare? KraneShares CSI China Internet ETF trades at $24.93 (market cap $4.37B), while Tilray Brands Inc trades at $3.54 (market cap $530.54M). The key difference: KraneShares CSI China Internet ETF is far larger — about 8.2× Tilray Brands Inc's market cap, and KraneShares CSI China Internet ETF is more actively traded (13,393,361 versus 9,099,075). Which is the better fit depends on your goals — on Pluang, investors hold KraneShares CSI China Internet ETF for 57 Days and Tilray Brands Inc for 31 Days on average.
| KWEB | TLRY | |
|---|---|---|
Market Cap | $4.37B | $530.54M |
Volume | 13,393,361 | 9,099,075 |
Sector | Sector/Thematic | Health |
52-Week High | $41.35 | $21.00 |
52-Week Low | $23.63 | $3.57 |
Typical Hold Time | 57 Days | 31 Days |
Enterprise Value | — | $684.46M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KWEB trades at $24.93, up 2.47% today but maintains a bearish technical outlook with all 13 moving averages signaling sell. The ETF faces headwinds from China's economic challenges including industrial overcapacity and weak domestic consumption. Recent institutional activity shows mixed sentiment with Tidal Investments reducing its stake by 39.1% while HSBC increased its position by 27.7% in recent quarters.
The China internet ETF remains under pressure from geopolitical tensions and economic rebalancing concerns. While corporate profits surged 26% in Q2 2026, ongoing U.S.-China trade dynamics and potential export curbs create uncertainty. Technical indicators suggest continued bearish momentum with key support at $24.
TLRY trades at $3.54, down 4.71% on the day and near 52-week lows, reflecting persistent bearish sentiment. The stock shows negative technical momentum with consecutive earnings misses and widening losses despite revenue growth. Recent financials reveal a net loss of $2.19B for 2025, though analyst consensus maintains a $65.01 price target with 25% buy ratings. Business developments include new product launches and leadership changes under Tilray's expanded beverage portfolio.
Outlook remains challenged by profitability concerns and high debt, but potential cannabis regulatory shifts could catalyze recovery. Investment opportunity hinges on execution improvement and market expansion, while risks include sustained cash burn and competitive pressures in the cannabis sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About KraneShares CSI China Internet ETF
KWEB tracks the CSI Overseas China Internet Index, providing exposure to Chinese software and services companies listed in the US and Hong Kong, including giants like Tencent, Alibaba, and Meituan.
Read more on KWEB →About Tilray Brands Inc
Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →
